Announcements Trials

Browse Landscape

Phase

Status

Completed 2 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Kidney Neoplasms 1 Carcinoma, Renal Cell 1

Interventions

pembrolizumab 437 Carboplatin 322 Nivolumab 292 Cyclophosphamide 281 Specimen Handling 271 Magnetic Resonance Spectroscopy 257 Cisplatin 253 Paclitaxel 248 Radiotherapy 229 Gemcitabine 183 Biopsy 182 Dexamethasone 181 durvalumab 168 atezolizumab 151 Rituximab 138 Doxorubicin 135 Lenalidomide 134 Bevacizumab 133 Docetaxel 131 Ipilimumab 129 Capecitabine 120 Radiation 118 Oxaliplatin 114 Radiosurgery 113 Pemetrexed 112 Etoposide 111 Fluorouracil 110 venetoclax 106 fludarabine 106 Prednisone 97

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × PT2385 × Clear all

NCT02293980 2024-06-17

MK-3795-001

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1 Active not recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡